Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation

Circulation: Heart Failure

Volumn 2, Issue 1, 2009, Pages 25-32

  Plante, Eric ^a   Lachance, Dominic ^a   Beaudoin, Jonathan ^a   Champetier, Serge ^a   Roussel, Élise ^a   Arsenault, Marie ^a   Couet, Jacques ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Heart diseases; Renin angiotensin system; Valves; Vasodilators

Indexed keywords

CAPTOPRIL; LOSARTAN; NIFEDIPINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE REGURGITATION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART DILATATION; HEART DISEASE; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HYPERVOLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTIC VALVE INSUFFICIENCY; CAPTOPRIL; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER; FOLLOW-UP STUDIES; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; NIFEDIPINE; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 77953654201     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.801548     Document Type: Article

References (29)

1. Bonow RO. Chronic aortic regurgitation. Role of medical therapy and optimal timing for surgery. Cardiol Clin. 1998; 16:449-461.
2. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla VS. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994; 331:689-694.
3. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med. 2005; 353:1342-1349.
4. Bonow RO, Carabello BA, Kanu C, de LA Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006; 114:e84-e231.
5. Mahajerin A, Gurm HS, Tsai TT, Chan PS, Nallamothu BK. Vasodilator therapy in patients with aortic insufficiency: a systematic review. Am Heart J. 2007; 153:454-461.
6. Plante E, Gaudreau M, Lachance D, Drolet MC, Roussel E, Gauthier C, Lapointe E, Arsenault M, Couet J. Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation. Can J Physiol Pharmacol. 2004; 82:191-199.
7. Couet J, Gaudreau M, Lachance D, Plante E, Roussel E, Drolet MC, Arsenault M. Treatment of combined aortic regurgitation and systemic hypertension: insights from an animal model study. Am J Hypertens. 2006; 19:843- 850.
8. Arsenault M, Plante E, Drolet MC, Couet J. Experimental aortic regurgitation in rats under echocardiographic guidance. J Heart Valve Dis. 2002; 11:128 -134.
9. Plante E, Couet J, Gaudreau M, Dumas MP, Drolet MC, Arsenault M.
10. Plante E, Lachance D, Champetier S, Drolet MC, Roussel E, Arsenault M, Couet J. Benefits of long-term {beta}-blockade in experimental chronic aortic regurgitation. Am J Physiol Heart Circ Physiol. 2008; 294: H1888-H1895.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402- 408.
12. Carabello BA. Vasodilators in aortic regurgitation-where is the evidence of their effectiveness? N Engl J Med. 2005; 353:1400 -1402.
13. Inamo J, Enriquez-Sarano M. Are vasodilators still indicated in the treatment of severe aortic regurgitation? Curr Cardiol Rep. 2007; 9: 87-92.
14. Zou Y, Yamazaki T, Nakagawa K, Yamada H, Iriguchi N, Toko H, Takano H, Akazawa H, Nagai R, Komuro I. Continuous blockade of L-type Ca2- channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats. Hypertens Res. 2002; 25:117-124.
15. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci (Lond). 2003; 104:341-347.
16. Cerbai E, Crucitti A, Sartiani L, De Paoli P, Pino R, Rodriguez ML, Gensini G, Mugelli A. Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res. 2000; 45:388 -396.
17. Borer JS, Truter S, Herrold EM, Falcone DJ, Pena M, Carter JN, Dumlao TF, Lee JA, Supino PG. Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload. Circulation. 2002; 105:1837-1842.
18. Drolet MC, Lachance D, Plante E, Roussel E, Couet J, Arsenault M. Gender-related differences in left ventricular remodeling in chronic severe aortic valve regurgitation in rats. J Heart Valve Dis. 2006; 15: 345-351.
19. Plante E, Lachance D, Gaudreau M, Drolet MC, Roussel E, Arsenault M, Couet J. Effectiveness of beta-blockade in experimental chronic aortic regurgitation. Circulation. 2004; 110:1477-1483.
20. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A, Seto S, Tsukazaki T, Kikuchi H, Yamashita S, Yano K. Norepinephrine enhances fibrosis mediated by TGF-beta in cardiac fibroblasts. Hypertension. 2002; 40: 148-154.
21. Lucero HA, Kagan HM. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci. 2006; 63:2304 -2316.
22. Sivakumar P, Gupta S, Sarkar S, Sen S. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem. 2008; 307:159 -167.
23. Miyazaki H, Oka N, Koga A, Ohmura H, Ueda T, Imaizumi T. Comparison of gene expression profiling in pressure and volume overloadinduced myocardial hypertrophies in rats. Hypertens Res. 2006; 29: 1029-1045.
24. Kato S, Spinale FG, Tanaka R, Johnson W, Cooper G, Zile MR. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol. 1995; 269:H863-H868.
25. Lachance D, Plante E, Roussel E, Drolet MC, Couet J, Arsenault M. Early left ventricular remodeling in acute severe aortic regurgitation: insights from an animal model. J Heart Valve Dis. 2008; 17:300 -308.
26. Akers WS, Cross A, Speth R, Dwoskin LP, Cassis LA. Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol. 2000; 279:H2797-H2806.
27. Kamide K, Rakugi H, Higaki J, Okamura A, Nagai M, Moriguchi K, Ohishi M, Satoh N, Tuck ML, Ogihara T. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens. 2002; 15:66 -71.
28. Laflamme A, Oster L, Cardinal R, de Champlain J. Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. Hypertension. 1997; 30: 278-287.
29. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril. J Hypertens. 2001; 19:465- 473. (Pubitemid 32195383)